Study of Optimal Treatment Plan in Hypertensives With Anti-AT1-Receptor Autoantibody
Information source: Huazhong University of Science and Technology
Information obtained from ClinicalTrials.gov on February 12, 2009
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Hypertension
Intervention: candesartan cilexetil (Drug)
Phase: Phase 4
Status: Recruiting
Sponsored by: Huazhong University of Science and Technology Official(s) and/or principal investigator(s):
Yu-Hua Liao, Study Director, Affiliation: Union Hospital, Tongji Medical College
Summary
The autoantibodies against AT1 receptor (ATR-AA), behaving like an agonist were detected in
patients with hypertension. ATR-AA which can blocked by ARB may play a role in the
pathogenesis of hypertension. The present study is to explore whether AT1 receptor blocker
has superior anti-hypertensive effect in patients with positive ATR-AA hypertension. Patients
with 2 grade hypertension were recruited and ATR-AA was assayed by ELISA. A study was carried
out and the efficacy of anti-hypertension was compared between candesartan cilexetil and ACE
inhibitor imidapril.
Clinical Details
Study design: Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study
Eligibility
Minimum age: 18 Years.
Maximum age: 80 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Hypertension (2 grade)
Exclusion Criteria:
- Secondary hypertension
- Known sensitivity or intolerance to an angiotensin II receptor antagonist or ACE
inhibitor
- Pregnancy
Locations and Contacts
Department of Cardiology, Wuhan Union Hospital, Wuhan, Hubei 430022, China; Recruiting
Yu-Hua Liao, Doctor, Phone: 00862785726376, Email: yumiaowei@vip.sina.com
Additional Information
Related publications: Liao YH, Wei YM, Wang M, Wang ZH, Yuan HT, Cheng LX. Autoantibodies against AT1-receptor and alpha1-adrenergic receptor in patients with hypertension. Hypertens Res. 2002 Jul;25(4):641-6.
Ending date: December 2006
Last updated: August 4, 2006
|
